Abstract
The prognosis of patients with acute lymphoblastic leukemia (ALL) and central nervous system (CNS) relapse has historically been very poor. Although chemo-radiotherapy has improved outcomes, some patients still have a poor prognosis after CNS relapse. Therefore, allogeneic hematopoietic stem cell transplantation (allo-SCT) has recently become an option for treatment of CNS leukemia; however, information, particularly on the long-term outcome of transplant recipients, is limited. We performed allo-SCT in eight pediatric patients with ALL (n=7) or T-cell type non-Hodgkin's lymphoma (n=1), who had isolated CNS relapse. All patients survived for a median of 70.5 (range, 13–153) months after SCT. Sequelae developed late in some patients: mental retardation (IQ=47) in one patient, severe alopecia in two patients, limited chronic graft-versus-host-disease in three patients, and amenorrhea and/or hypothyroidism in three patients. Except for a pre-school child with post transplant CNS relapse, six out of seven patients show normal school/social performance. Our results clearly indicate a high cure rate of isolated CNS relapse by allo-SCT in pediatric lymphoid malignancies; however, there needs to be further studies to determine which are the appropriate candidates for transplantation and what is the best transplant regimen to achieve high cure rate and maintain good quality of life.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pui C-H, Relling MV, Parm D, Downing JR . Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535–1548.
Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211–1218.
Schrappe M, Reiter A, Ludwig W-D, Harbott J, Zimmermann M, Niemeyer C et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood 2000; 95: 3310–3322.
Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995. Leukemia 2000; 14: 2223–2233.
Chessells JM . Relapsed lymphoblastic leukaemia in children: a continuing challenge. Br J Haematol 1998; 102: 423–438.
Pinkel D, Woo S . Prevention and treatment of meningeal leukemia in children. Blood 1994; 84: 355–366.
Pui C-H, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104: 2690–2696.
Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991–1996). Leukemia 2002; 16: 1099–1111.
Hill FGH, Richards S, Gibson B, Hann I, Lilleyman J, Kinsey S et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol 2004; 124: 33–46.
Pui C-H, Mahmoud HH, Rivera GK, Hancock ML, Sandlund JT, Behm FG et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 1998; 92: 411–415.
Lauer SJ, Shuster JJ, Mahoney Jr DH, Winick N, Toledano S, Munoz L et al. A comparison of early intensive methotrexate/mercaptropurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial. Leukemia 2001; 15: 1038–1045.
Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A et al. Value of high-dose cytarabine during interval therapy of a Berlin–Frankfurt–Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the Europian Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol 2001; 19: 1935–1942.
Conter V, Arico M, Valsecchi MG, Rizzari C, Testi AM, Messina C et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin–Frankfurt–Munster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. J Clin Oncol 1995; 13: 2497–2502.
Nathan PC, Maze R, Spiegler B, Greenberg ML, Weitzman S, Hitzler JK . CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: high-dose methotrexate versus cranial irradiation. Pediatr Blood Cancer 2004; 42: 24–29.
Yumura-Yagi K, Hara J, Horibe K, Tawa A, Komada Y, Oda M et al. Outcome after relapse in childhood acute lymphoblastic leukemia. Int J Hematol 2002; 76: 61–68.
Borgmann A, von Stackelberg A, Hartmann R, Ebell W, Klingebiel T, Peters C et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003; 101: 3835–3839.
Bordigoni P, Esperou H, Souillet G, Pico J, Michel G, Lacour B et al. Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle study. Br J Haematol 1998; 102: 656–665.
Nagatoshi Y, Kawano Y, Nagayama J, Okamura J . Treatment of isolated central nervous system relapse in high-risk lymphoid malignancy with allogeneic bone marrow transplantation and extended intrathecal therapy. Br J Haematol 2004; 125: 766–768.
Messina C, Valsecchi MG, Aricò M, Locatelli F, Rossetti F, Rondelli R et al. Autologous bone marrow transplantation for treatment of isolated central nervous system relapse of childhood acute lymphoblastic leukemia. Bone Marrow Transplant 1998; 21: 9–14.
Schroeder H, Garwicz S, Kristinsson J, Siimes MA, Wesenberg F, Gustafsson G . Outcome after first relapse in children with acute lymphoblastic leukemia: a population-based study of 315 patients from the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Med Pediatr Oncol 1995; 25: 372–378.
Wheeler K, Richards S, Bailey C, Chessells J . Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Br J Haematol 1998; 101: 94–103.
Borgmann A, Hartmann R, Schmid H, Klingebiel T, Ebell W, Göbel U et al. Isolated extramedullary relapse in children with acute lymphoblastic leukemia: a comparison between treatment results of chemotherapy and bone marrow transplantation. Bone Marrow Transplant 1995; 15: 515–521.
Ritchey AK, Pollock BH, Lauer SJ, Andejeski Y, Buchanan GR . Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study. J Clin Oncol 1999; 17: 3745–3752.
Morris EC, Harrison G, Bailey CC, Hann IM, Hill FG, Gibson BES et al. Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemia. Br J Haematol 2003; 120: 787–789.
Longeway K, Mulhern R, Crisco J, Kun L, Lauer S, Casper J et al. Treatment of meningeal relapse in childhood acute lymphoblastic leukemia: II. A prospective study of intellectual loss specific to CNS relapse and therapy. Am J Pediatr Hematol Oncol 1990; 12: 45–50.
Kreuger A, Garwicz S, Hertz H, Jonmundsson G, Lanning M, Lie SO et al. Central nervous system disease in childhood acute lymphoblastic leukemia: prognostic factors and results of treatment. Pediatr Hematol Oncol 1991; 8: 291–299.
Winick NJ, Smith SD, Shuster J, Lauer S, Wharam MD, Land V et al. Treatment of CNS relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1993; 11: 271–278.
Gelber RD, Sallan SE, Cohen HJ, Donnelly M, Dalton V, Tobia F et al. Central nervous system treatment in childhood acute lymphoblastic leukemia. Cancer 1993; 72: 261–270.
von der Weid N, Wagner B, Angst R, Arnet B, Baumgartner C, Beck D et al. Treatment of relapsing acute lymphoblastic leukemia in childhood. III. Experiences with 54 first bone marrow, nine isolated testicular, and eight isolated central nervous system relapse observed 1985–1989. Med Pediatr Oncol 1994; 22: 361–369.
Kumar P, Kun LE, Hustu HO, Mulhern RK, Hancock ML, Coffey D et al. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys 1995; 31: 477–483.
van den Berg H, Odink AE, Behrendt H . Delayed craniospinal irradiation for a first isolated central nervous relapse of acute lymphoblasic leukemia: report on 14 cases. Med Pediatr Oncol 2000; 34: 402–406.
Gaynon PS, Qu RP, Chappell RJ, Willoughby MLN, Tubergen DG, Steinherz PG et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse – the Children’s Cancer Group experience. Cancer 1998; 82: 1387–1395.
Ribeiro RC, Rivera GK, Hudson M, Mulhern RK, Hancock ML, Kun L et al. An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol 1995; 13: 333–338.
Morimoto A, Kuriyama K, Hibi S, Todo S, Yoshihara T, Kuroda H et al. Prognostic value of early response to treatment combined with conventional risk factors in pediatric acute lymphoblastic leukemia. Int J Hematol 2005; 81: 228–234.
Shimada M, Meguro K, Inagaki H, Ishizaki J, Yamadori A . Global intellectual deterioration in Alzheimer’s disease and a reverse model of intellectual development: an applicability of the Binet scale. Phychiatry Clin Neurosci 2001; 55: 559–563.
Yoshihara T, Naya M, Tsunamoto K, Hojo M, Hibi S, Morimoto A et al. A preparatory regimen of total body irradiation, busulphan and melphalan for allogeneic bone marrow transplantation in childhood high-risk leukemia and lymphoma. Anticancer Res 2003; 23: 1739–1742.
Cohen A, Duell T, Socie G, van Lint MT, Weiss M, Tichelli A et al. Nutritional status and growth after bone marrow transplantation (BMT) during childhood: EBMT Late-Effects Working Party retrospective data. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1999; 23: 1043–1047.
Cohen A, Rovelli A, Bakker B, Uderzo C, van Lint MT, Esperou H et al. Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. Blood 1999; 15: 4109–4115.
Ishiguro H, Yasuda Y, Tomita Y, Shinagawa T, Shimizu T, Morimoto T et al. Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence. J Clin Endocrinol Metab 2004; 89: 5981–5986.
Jankovic M, Brouwers P, Valsecchi MG, Van Veldhuizen A, Huisman J et al. Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukemia. ISPACC. International Study Group on Psychosocial Aspects of Childhood Cancer. Lancet 1994; 344: 224–227.
Belasco JB, Goldwein JW, Simms S, Griffin G, D’Angio G, Lange B . Hypofractionated moderate dose radiation, intrathecal chemotherapy, and repetitive reinduction/reconsolidation systemic therapy for central nervous system relapse of acute lymphoblastic leukemia in children. Med Pediar Oncol 2000; 34: 125–131.
Ganem G, Kuentz M, Bernaudin F, Gharbi A, Cordonnier C, Lemerle S et al. Central nervous system relapses after bone marrow transplantation for acute lymphoblastic leukemia in remission. Cancer 1989; 64: 1796–1804.
Hibi S, Tsunamoto K, Todo S, Sawada T, Ueda Y, Taniwaki M et al. Chimerism analysis on mononuclear cells in the CSF after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 20: 503–506.
Yoshihara T, Hibi S, Yamane Y, Morimoto A, Hashida T, Iwami H et al. Numerous nonclonal chromosomal aberrations arising in residual recipient hematopoietic cells following allogeneic bone marrow transplantation. Bone Marrow Transplant 2005; 35: 587–589.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yoshihara, T., Morimoto, A., Kuroda, H. et al. Allogeneic stem cell transplantation in children with acute lymphoblastic leukemia after isolated central nervous system relapse: our experiences and review of the literature. Bone Marrow Transplant 37, 25–31 (2006). https://doi.org/10.1038/sj.bmt.1705202
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705202
Keywords
This article is cited by
-
Hematopoietic stem cell transplantation for isolated extramedullary relapse of acute lymphoblastic leukemia in children
Bone Marrow Transplantation (2019)
-
Unrelated cord blood transplantation for central nervous system relapse in high-risk childhood acute lymphoblastic leukemia
Annals of Hematology (2013)
-
Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985–2001
Leukemia (2010)
-
Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research
Leukemia (2008)